IDH2 and central nervous system cancer: Eichkorn and colleagues, in their study titled “Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3,“ analyzed 194 patients treated with PRT from 2010 to 2020 [13].